ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Down 25.0% in January

ABVC BioPharma, Inc. (NASDAQ:ABVC) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 220,000 shares, a decrease of 25.0% from the January 15th total of 293,400 shares. Based on an average daily trading volume, of 197,200 shares, the short-interest ratio is presently 1.1 days. Currently, 2.0% of the company’s stock are sold short.

Hedge Funds Weigh In On ABVC BioPharma

An institutional investor recently raised its position in ABVC BioPharma stock. Avantax Planning Partners Inc. increased its holdings in shares of ABVC BioPharma, Inc. (NASDAQ:ABVC) by 269.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 143,968 shares of the company’s stock after purchasing an additional 104,968 shares during the quarter. Avantax Planning Partners Inc. owned approximately 1.11% of ABVC BioPharma worth $85,000 as of its most recent SEC filing. 11.38% of the stock is owned by hedge funds and other institutional investors.

ABVC BioPharma Stock Performance

NASDAQ:ABVC opened at $0.46 on Friday. The stock has a 50-day simple moving average of $0.52 and a 200 day simple moving average of $0.59. ABVC BioPharma has a 52-week low of $0.40 and a 52-week high of $1.73. The company has a market cap of $5.92 million, a PE ratio of -0.53 and a beta of 0.67.

About ABVC BioPharma

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.